Introduction {#Sec1}
============

Nephrolithiasis is a common urological disease affecting 1--13% of the general population^[@CR1]^. In the United States, approximately 12% of men and 5% of women are affected by nephrolithiasis during their lifetimes^[@CR2]^. Kidney stones left untreated may lead to haematuria, renal colitis, urinary infection and urinary obstruction, which would result in hydronephrosis, renal function impairment and finally renal function insufficiency. Besides, after the first occurrence of nephrolithiasis, the risk of recurrence is 40% within 5 years, 60% within 10 years and 75% within 20 years^[@CR3]^. The causes of nephrolithiasis are likely to involve multiple factors, including climate, diet and genetic background. It is reported that 75% of stones are composed of calcium; of these, calcium oxalate (CaOx) stone is the most common type^[@CR4]^. However, the mechanism of CaOx stone formation has not been completely clarified, and there are no ideal clinical methods for preventing kidney stones.

Based on clinical and experimental data, it is becoming obvious that stone formation is not a simple physicochemical disorder. The formation of a CaOx stone starts with supersaturation and crystallization of CaOx in the renal tubular lumen^[@CR5]^. It has been reported that CaOx crystals trigger tissue inflammation via NLRP3 inflammasome- and caspase-1-mediated secretion of IL-1β and IL-18^[@CR6]^. However, these crystals also exert direct cytotoxic effects by promoting apoptotic cell death^[@CR7]^. Crystal deposits adhere to injured and dead renal tubular epithelial cells (TECs), which leads to further crystal retention and aggregation^[@CR8]^. Therefore, necrosis^[@CR9]^ and apoptosis^[@CR10]^ of renal TEC, especially renal proximal TEC, play a key role in CaOx kidney stone formation^[@CR11],[@CR12]^.

Seven subtypes of sirtuins have been identified in mammals, and sirtuins play major roles in protecting against cellular stress and in controlling metabolic pathways^[@CR13]^. Sirtuin 3 (sirt3), which is a NAD^+^-dependent protein deacetylase, regulates acetylated substrate peptides^[@CR14]^, maintains energy homoeostasis^[@CR15],[@CR16]^ and suppresses palmitate-induced ROS production and inflammation in proximal TEC^[@CR17]^. However, the role of Sirt3 in the pathophysiology of nephrolithiasis remains to be illustrated. We hypothesized that Sirt3 could inhibit CaOx-induced cell death in renal TEC during kidney stone formation. Therefore, in this study, we investigated the function and mechanism of Sirt3 in CaOx-induced TEC injury in vivo and in vitro, and the upstream signalling pathway for Sirt3 gene regulation.

Materials and Methods {#Sec2}
=====================

Animal experiment {#Sec3}
-----------------

All animal experiments were performed according to the Guidelines for the Care and Use of Laboratory Animals of the Laboratory Animal Ethics Committee of the Second Military Medical University with good animal surgical research practices and were approved by the Laboratory Animal Ethics Committee of the Second Military Medical University (20180906057).

Clinical specimens {#Sec4}
------------------

All samples were collected from patients in the Department of Urology, Shanghai Changhai hospital (Shanghai, China) with informed consent, and ethical approval was granted from the Shanghai Changhai Hospital Ethics Committee (CHEC2017-217). Normal control specimens were obtained from radical resection of the kidney, and kidney needle biopsy tissues were taken from renal calculi patients.

Assessment of renal injury {#Sec5}
--------------------------

Creatinine and urea nitrogen levels were detected in blood and urine samples. Paraffin sections were used for in situ end labelling (ISEL) of fragmented DNAs with digoxigenindeoxyuridine by terminal deoxynucleotidyl transferase using an Apoptosis Detection Kit (Millipore, Billerica, MA, USA). Apoptotic cells were examined at 400 × magnification over 20 fields of tubulointerstitial areas and semi-quantitatively scored^[@CR18]^. The expression of neutrophil gelatinase-associated lipocalin (NGAL) was measured in both serum and urine using the NGAL ELISA kit (R&D Systems, Minneapolis, MN, USA).

Assessment of oxidation {#Sec6}
-----------------------

The intracellular ROS level was measured using an ROS detection kit (\#E004, Nanjing Jiancheng Bioengineering Institute, Nanjing, China). In brief, the single-cell suspension was obtained from murine kidneys, and added with 10 μM 2,7-dichlorofluorescin diacetate (DCFH-DA). The cells were incubated for 30 min at 37 °C, and then centrifuged at 1000 × *g* for 5 min. After washing for two times with PBS, the fluorescence units (RFU) was detected at excitation/emission wavelengths of 485/525 nm.

Immunohistochemistry {#Sec7}
--------------------

Immunohistochemical staining for Sirt3 (Cell Signaling Technology, 1:1000) was performed on kidney sections using a DAKO ChemMate EnVision Detection Kit (DAKO, Carpinteria, CA, USA) as previously described^[@CR19],[@CR20]^.

Western blot analysis {#Sec8}
---------------------

Membrane proteins were separated on sodium dodecyl sulphate (SDS)--polyacrylamide gels and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5% milk and incubated overnight with indicated antibodies. The results were analyzed as previously described^[@CR19],[@CR21],[@CR22]^.

Cell culture and in vitro model {#Sec9}
-------------------------------

Murine renal tubular epithelial cells (TCMK-1) were purchased from the American Type Culture Collection (ATCC) and cultured in DMEM/F12 medium containing 10% FBS. TCMK-1 cells were seeded on six-well plates (1 × 10^5^ cells/well) and cultured for 24 h. Under CaOx stimulation at different concentrations (0, 10, 100 or 1000 μg/ml), cells were cultured for 24, 48 or 72 h and then harvested and processed for western blot and flow cytometry analyses.

Flow cytometry for detection of apoptosis and necrosis {#Sec10}
------------------------------------------------------

Cell apoptosis was detected with an Annexin V-FITC Apoptosis Detection Kit (Merck, Darmstadt, Germany) as noted previously^[@CR23]^. The experiment was repeated at least three times.

Statistical analysis {#Sec11}
--------------------

Data are presented as the means ± standard deviation (SD). Statistical analysis (SPSS18.0 software, SPSS Inc., Armonk, NY, USA) was performed with two-tailed independent Student's *t* tests after the demonstration of homogeneity of variance with the F test or one-way ANOVA for more than two groups. The Scheffe test was used for post hoc analysis. Statistical significance was set as *p* \< 0.05.

Results {#Sec12}
=======

Sirt3 expression was suppressed in nephrolithiasis in vivo and in vitro {#Sec13}
-----------------------------------------------------------------------

As a verification of glyoxylic acid-induced nephrolithiasis model establishment, von Kossa staining showed calcium deposits in the kidney (Figure [S1A](#MOESM1){ref-type="media"}). The serum creatinine and urine nitrogen levels were significantly increased after glyoxylic acid treatment (Fig. [1a](#Fig1){ref-type="fig"}). NGAL is a sensitive marker of TEC injury^[@CR24]^, and the level of NGAL in urine was significantly increased in the glyoxylic acid group compared to the control group (Fig. [1b](#Fig1){ref-type="fig"}). In addition, ROS activity in the kidney was upregulated (Fig. [1c](#Fig1){ref-type="fig"}). The number of ISEL^+^ cells was dramatically increased in the glyoxylic acid-induced nephrolithiasis group compared to the control group (Fig. [1d](#Fig1){ref-type="fig"}).Fig. 1Sirt3 expression was inhibited in nephrolithiasis in vivo.**a** In the glyoxylic acid-induced nephrolithiasis model, creatinine and urea nitrogen levels in both serum and urine were significantly increased relative to the control levels. **b** Glyoxylic acid treatment increased the urine NGAL level, but the serum NGAL level showed no difference between the glyoxylic acid and control treatments. **c** ROS activity in the kidney was upregulated in the glyoxylic acid group compared to the control group. **d** The in situ end labelling (ISEL) assay showed more apoptotic cells in the kidney following glyoxylic acid treatment. Scale bar: 50 μm. **e** The top pathways of differentially expressed (DE) genes between normal and glyoxylic acid-treated murine kidney samples are shown in the histogram. The Venn diagram shows the number of upregulated (upward arrow) and downregulated (downward arrow) DE genes associated with the mitochondrion, ROS and the MAPK cascade. Heat map of the fold change in expression (ratio of the normalized intensities). Among the 29 upregulated and eight downregulated genes, Sirt3 was the only gene in all three subgroups that was downregulated (Case: glyoxylic acid-treated mice model; Control: saline-treated control mice). **f** In the glyoxylic acid group, the Sirt3 expression level was significantly decreased in both the cortex and medulla (*n* = 5). Scale bar: 250 μm. **g** Western blot analysis showed decreased Sirt3 and Bcl-2 levels and increased Bax levels in the glyoxylic acid group. **h** Sirt3 expression was downregulated in renal calculi patients compared with normal control; left: normal control samples from radical resection of the kidney; right: kidney needle biopsy tissues. Data are shown as the means ± S.D.; *n* = 5 patients per group. Scale bar: 500 μm (left); 100 μm (right)

We compared the gene expression profile between control and glyoxylic acid-treated murine kidney samples. Mitochondrial dysfunction and abnormal ROS generation have been demonstrated to promote the kidney stone formation and epithelial cell injury^[@CR25]--[@CR27]^. The MAPK signalling pathway is the top regulated pathway in our gene expression profiling data. These three important pathways lead us to identify the potential key candidate, Sirt3, participating in kidney stone formation, development and pathology (Fig. [1e](#Fig1){ref-type="fig"}). To confirm the gene array results, we performed immunohistochemical staining for Sirt3 in the kidney. Sirt3 expression was significantly reduced in both the cortex and the medulla of the kidney samples from the glyoxylic acid-treated group (Fig. [1f](#Fig1){ref-type="fig"}). Additionally, western blot analysis showed an increased level of Bax and a decreased level of Bcl-2 in the kidney following glyoxylic acid treatment (Fig. [1f](#Fig1){ref-type="fig"}), suggesting that glyoxylic acid induced apoptosis in the kidney. Decreased Sirt3 protein expression was further confirmed by western blot (Fig. [1g](#Fig1){ref-type="fig"}). The downregulation of Sirt3 is not only observed in mice kidney injury model, but also in the kidney biopsy samples from renal calculi patients (Fig. [1h](#Fig1){ref-type="fig"}).

To investigate the induction of TEC death in the nephrolithiasis model, we performed in vitro experiments using CaOx stimulation. We found that CaOx induced TEC apoptosis and necrosis in a dose- and time-dependent manner (Figure [S1B, C](#MOESM1){ref-type="media"}). The level of Sirt3 was reduced as the CaOx concentration increased (Figure [S1D](#MOESM1){ref-type="media"}). Following stimulation with 1000 μg/ml CaOx, Sirt3 was significantly downregulated (Figure [S1E](#MOESM1){ref-type="media"}). ROS activity was upregulated with increasing CaOx concentration and stimulation time (Figure [S1F](#MOESM1){ref-type="media"}).

Suppressing Sirt3 expression exacerbated CaOx-induced cell death in vitro {#Sec14}
-------------------------------------------------------------------------

It was suggested that downregulation of Sirt3 was highly associated with kidney injury. We were wondering whether suppressing Sirt3 could deteriorate renal tubular epithelial cell apoptosis and necrosis. To verify this hypothesis, we silenced *sirt3* expression in TEC with Sirt3 siRNA. Flow cytometry analysis showed that CaOx treatment increased TEC apoptosis and necrosis under the condition of Sirt3 silencing compared to the control siRNA (Fig. [2a](#Fig2){ref-type="fig"}). In addition, ROS activity was significantly upregulated following CaOx treatment in the Sirt3 siRNA-transfected group compared to the control siRNA-transfected group (Fig. [2b](#Fig2){ref-type="fig"}). At the protein level, *sirt3* silencing was confirmed by the decrease in Sirt3 expression. Next, we examined the levels of the pro-apoptotic protein cleaved caspase-3 and the anti-apoptotic protein Bcl-2 with or without Sirt3 siRNA treatment. The results demonstrated that TEC apoptosis significantly increased, following CaOx application in the Sirt3 siRNA-transfected group compared with the control siRNA-transfected group (Fig. [2c](#Fig2){ref-type="fig"}). These results indicated that suppressing Sirt3 expression exacerbated CaOx-induced cell death.Fig. 2Suppressing Sirt3 expression exacerbated CaOx-induced cell death in vitro.**a** Flow cytometry analysis showed that silencing *sirt3* increased TEC apoptosis and necrosis in the presence of CaOx. **b** ROS activity was significantly upregulated by Sirt3 siRNA transfection. **c** Western blot showed the expression of Sirt3, cleaved caspase-3 and Bcl-2 with Sirt3 or control siRNA transfection. Sirt3 siRNA transfection effectively inhibited Sirt3 protein expression. In the Sirt3 siRNA group, cleaved caspase-3 expression was significantly increased, and Bcl-2 expression was decreased. Data are shown as the means ± S.D.; *n* = 3 per group

Overexpression of Sirt3 or enhancing its activity rescued the kidney from CaOx-induced cell death in vitro and in vivo {#Sec15}
----------------------------------------------------------------------------------------------------------------------

In addition to silencing *sirt3*, we also generated *sirt3*-overexpressing TEC (Figure [S2A](#MOESM2){ref-type="media"}). Overexpression of *sirt3* rescued CaOx-induced apoptosis and necrosis of TEC in vitro (Fig. [3a](#Fig3){ref-type="fig"}). Moreover, ROS activity was decreased in the *sirt3*-overexpressing group (Fig. [3b](#Fig3){ref-type="fig"}). Sirt3 protein expression was rescued in the *sirt3*-overexpressing group under CaOx stimulation (Figure [S2A](#MOESM2){ref-type="media"}). The cleaved caspase-3 and Bax levels were significantly decreased, and the Bcl-2 level was increased in the *sirt3*-overexpressing group compared to the control group (Fig. [3c](#Fig3){ref-type="fig"}). These results revealed that Sirt3 reduced TEC apoptosis and necrosis.Fig. 3Overexpression Sirt3 or enhancing its activity rescued the kidney from CaOx-induced cell death in vitro and in vivo.**a** Flow cytometry showed that overexpression of *sirt3* blocked CaOx-induced apoptosis and necrosis of TEC. **b** Overexpression of *sirt3* significantly reduced ROS levels under CaOx stimulation. **c** Sirt3 protein expression was rescued in the *sirt3*-overexpressing group under CaOx stimulation. The cleaved caspase-3 and Bax levels were significantly decreased, and the Bcl-2 level was increased in the *sirt3*-overexpressing group compared to the non-transfected control group. **d** The von Kossa staining results revealed that resveratrol reduced calcium deposits in the medulla of the murine nephrolithiasis model. Scale bar: 100 μm (left); 50 μm (right). **e** Sirt3 expression in both the renal cortex and medulla was increased by resveratrol treatment. Data are shown as the means ± S.D.; *n* = 6 mice per group. Scale bar: 100 μm (left); 50 μm (right)

Next, we investigated whether activation of Sirt3 in vivo could ameliorate nephrolithiasis. Resveratrol, which has been used as a Sirt3 agonist^[@CR28]--[@CR30]^, could upregulate Sirt3 expression at both mRNA and protein levels in TEC in vitro (Figure [S2B, C](#MOESM2){ref-type="media"}). Resveratrol was then injected into mice to increase Sirt3 expression. Resveratrol reduced calcium deposits in the medulla based on von Kossa staining (Fig. [3d](#Fig3){ref-type="fig"}) in vivo and decreased TEC apoptosis and necrosis in vitro (Figure [S2D](#MOESM2){ref-type="media"}). Sirt3 expression also increased in the renal cortex and medulla following resveratrol injection (Fig. [3e](#Fig3){ref-type="fig"}). All the results above confirmed that high expression and activation of Sirt3 are required for maintaining kidney homoeostasis and protecting from CaOx-induced cell death.

Inhibition of the MAPK pathway restored Sirt3 expression and ameliorated tubular and renal injury in vitro and in vivo {#Sec16}
----------------------------------------------------------------------------------------------------------------------

Next, we investigated the mechanism of CaOx-mediated Sirt3 inhibition. We screened several common pathways using different inhibitors. PDTC (NF-κB inhibitor), SRP1/2 (mTOR inhibitor), Ly294002 (PI3K inhibitor), rapamycin (mTOR inhibitor), AZD1480 (JakStat inhibitor) and GO6976 (PKCα/PKCβ1 inhibitor) treatment did not change the expression level of Sirt3 compared with the control group (Fig. [4a](#Fig4){ref-type="fig"}). However, SB203580 (P38 inhibitor), PD98059 (JNK inhibitor) and SP6000125 (ERK inhibitor) treatment significantly increased Sirt3 expression (Fig. [4a](#Fig4){ref-type="fig"}). These results suggested that the MAPK pathway probably mediated the CaOx-induced inhibition of Sirt3 expression. Then, we performed cell apoptosis and necrosis analyses (Fig. [4b](#Fig4){ref-type="fig"}). SB203580, PD98059 and SP6000125 reduced TEC apoptosis and necrosis under CaOx stimulation, indicating that inhibiting the MAPK pathway blocked CaOx-mediated cytotoxicity (Fig. [4c](#Fig4){ref-type="fig"}). Next, we verified the activation of MAPK signalling in CaOx-mediated TEC injury. The phosphorylation levels of ERK, JNK and P38 were increased in a time-dependent manner under CaOx stimulation (Fig. [4d](#Fig4){ref-type="fig"}). Finally, to further check whether the renal protective effects of MAPK inhibitors are dependent on Sirt3, we compared the TEC apoptosis and necrosis level by those inhibitors treatment after *sirt3* knockdown. Inhibition of MAPK signalling by SB203580, PD98059 and SP6000125 restored Sirt3 expression but reversed by *sirt3* siRNA treatment (Figure [S3A, B](#MOESM3){ref-type="media"}). The TEC apoptosis and necrosis were increased with *sirt3* knockdown; however, MAPK inhibitors could not rescue the TEC from death once sirt3 is silent (Fig. [4e](#Fig4){ref-type="fig"}). These results confirmed that MAPK inhibitors could directly or indirectly target sirt3 transcription to regulate kidney inflammation and cell death.Fig. 4Suppression of Sirt3 expression in nephrolithiasis in vitro was dependent on activation of the MAPK pathway.**a** SB203580 (P38 inhibitor), PD98059 (JNK inhibitor) and SP6000125 (ERK inhibitor) significantly increased Sirt3 expression, while PDTC (NF-κB inhibitor), SRP1/2 (mTOR inhibitor), Ly294002 (PI3K inhibitor), rapamycin (mTOR inhibitor), AZD1480 (JakStat inhibitor) and GO6976 (PKCα/PKCβ1 inhibitor) decreased Sirt3 expression. **b** These inhibitors were used to determine the pathways responsible for apoptosis and necrosis under CaOx stimulation. **c** SB203580 (P38 inhibitor), PD98059 (JNK inhibitor) and SP6000125 (ERK inhibitor) significantly reduced apoptosis and necrosis. **d** The phosphorylation levels of ERK, JNK and P38 were increased in a time-dependent manner under CaOx stimulation. **e** TEC apoptosis and necrosis were increased with *sirt3* knockdown. Data are shown as the means ± S.D.; *n* = 3 per group

To verify the above-described mechanism in vivo, we treated mice with SB203580, PD98059 and SP6000125 to inhibit the MAPK pathway in an in vivo nephrolithiasis model. SB203580, PD98059 or SP6000125 treatment significantly decreased serum creatinine, blood urea nitrogen and serum NGAL (Fig. [5a--c](#Fig5){ref-type="fig"}) levels, suggesting that inhibiting MAPK signalling protected renal function in this nephrolithiasis model. Additionally, von Kossa staining revealed that SB203580, PD98059 or SP6000125 treatment reduced calcium deposits in the kidney (Fig. [5d](#Fig5){ref-type="fig"}), and recovered Sirt3 expression in vivo (Fig. [5e](#Fig5){ref-type="fig"}). These data demonstrated that CaOx-mediated nephrolithiasis is dependent on activation of the MAPK pathway.Fig. 5Inhibition of the MAPK pathway ameliorated glyoxylic acid-induced nephrolithiasis and kidney injury in vivo.Mice were treated with SB203580, PD98059 and SP6000125 in vivo to inhibit the MAPK pathway in a nephrolithiasis model. **a**--**c** Inhibition of the MAPK pathway decreased serum creatinine, blood urea nitrogen and serum NGAL levels. **d** The von Kossa staining revealed that SB203580, PD98059 or SP6000125 treatment reduced calcium deposits in the kidney. **e** The expression levels of Sirt3 were significantly increased by SB203580, PD98059 or SP6000125 treatment (*n* = 3). Scale bar: 250 μm. Data are shown as the means ± S.D.; *n* = 6 mice per group

Sirt3 directly deacetylates FoxO3a to protect TEC from apoptosis {#Sec17}
----------------------------------------------------------------

Functional FoxO3a facilitated the transcription of anti-apoptotic and antioxidant genes^[@CR31]^. FoxO3a localization to the cytoplasm not only deactivates FoxO3a but also represents a crucial step leading to FoxO3a degradation. The acetylation status of FoxO3a affects its DNA-binding ability and transcriptional activity but not its intracellular localization^[@CR32]^. Sirt3 upregulation with resveratrol decreased acetylated FoxO3a expression in the kidney in vivo (Fig. [6a](#Fig6){ref-type="fig"}). Moreover, acetylation of FoxO3a in the murine kidney was reduced by SB203580, PD98059 or SP6000125 treatment (Figure [S4A](#MOESM4){ref-type="media"}). Similarly, overexpression of Sirt3 in TEC in vitro significantly decreased the FoxO3a acetylation level under CaOx stimulation (Fig. [6b](#Fig6){ref-type="fig"}). Immunofluorescence indicated that Sirt3 interacted with FoxO3a most abundantly around the nucleus (Fig. [6c](#Fig6){ref-type="fig"}), suggesting that Sirt3 directly deacetylates FoxO3a. Co-immunoprecipitation (co-IP) assays confirmed the interaction between Sirt3 and FoxO3a (Fig. [6d](#Fig6){ref-type="fig"}). In addition, phosphorylation of FoxO3a at Ser253 was found to affect its intracellular localization and inhibit its transcriptional activity^[@CR33]^. We found that CaOx upregulated the phosphorylation levels of FoxO3a at Ser253 and Ser318/321, while Sirt3 overexpression reversed this effect (Figure [S4B](#MOESM4){ref-type="media"}). In addition, ubiquitination reduces FoxO3a activity and function^[@CR34]^. Using co-IP assays, we also found that overexpression of Sirt3 blocked CaOx-induced FoxO3a ubiquitination in TEC (Figure [S4C](#MOESM4){ref-type="media"}).Fig. 6Sirt3 directly deacetylated FoxO3a to protect TEC from apoptosis and necrosis.**a** Immunoprecipitation assays demonstrated that Sirt3 overexpression via resveratrol treatment decreased acetylated FoxO3a expression in the kidney in vivo. **b** Similarly, overexpression of Sirt3 in TEC in vitro significantly decreased the FoxO3a acetylation level under CaOx stimulation. **c** Immunofluorescence assays indicated that Sirt3 interacted with FoxO3a most abundantly around the nucleus (DAPI: blue, FoxO3a: green and Sirt3: red). Scale bar: 60 μm. **d** Co-immunoprecipitation (co-IP) assays confirmed the interaction between Sirt3 and FoxO3a. **e** Overexpression of a catalytic mutant of Sirt3 (*Sirt3*^*H248Y*^) did not influence FoxO3a acetylation. **f** Overexpression of *Sirt3*^*H248Y*^ did not reduce ROS activity in TEC. **g** Overexpression of *Sirt3*^*H248Y*^ did not decrease TEC necrosis under CaOx stimulation. **h** Overexpression of *Sirt3*^*H248Y*^ increased cleaved caspase-3 and Bax expression and reduced Bcl-2 expression. Data are shown as the means ± S.D.; *n* = 6 mice per group for an in vivo experiment. *n* = 3 per group for an in vitro experiment

Sirt3 is a NAD+-dependent protein deacetylase that regulates global protein acetylation^[@CR31]^. Therefore, to test whether the deacetylase activity of Sirt3 is required for its functions of FoxO3a activity regulation and TEC protection, we generated a catalytic mutant of Sirt3 (*Sirt3*^*H248Y*^) lacking deacetylase activity. Mutation of Sirt3 did not influence its overexpression in TEC (Figure [S5A](#MOESM5){ref-type="media"}). The levels of acetylation, phosphorylation and ubiquitination of FoxO3a were detected by western blot and immunoprecipitation. As expected, overexpression of *Sirt3*^*H248Y*^ did not decrease the levels of FoxO3a acetylation, phosphorylation and ubiquitination under CaOx stimulation (Fig. [6e](#Fig6){ref-type="fig"}, Figure [S5B](#MOESM5){ref-type="media"}). Moreover, overexpression of *Sirt3*^*H248Y*^ increased ROS activity (Fig. [6f](#Fig6){ref-type="fig"}) and necrosis (Fig. [6g](#Fig6){ref-type="fig"}) under CaOx stimulation. Additionally, the catalytic mutant of Sirt3 promoted cleaved caspase-3 and Bax expression and reduced Bcl-2 expression (Fig. [6h](#Fig6){ref-type="fig"}). These results indicated that a deficiency in the deacetylase activity of Sirt3 completely reversed Sirt3-mediated cytoprotection.

The Sirt3/FoxO3a pathway promotes autophagy in TEC {#Sec18}
--------------------------------------------------

Autophagy, which has been proposed as a third mode of cell death, is a process in which cells generate energy and metabolites by digesting their own organelles and macromolecules. Autophagy allows a starving cell, or a cell that is deprived of growth factors, to survive^[@CR35]^. We previously found that induction of autophagy protected renal TEC against injury^[@CR23]^. In the current study, we found that Sirt3 overexpression significantly induced autophagy, as demonstrated by an increased LC3 II/I ratio, as well as upregulated the expression of Beclin-1, Atg5 and Atg7 under CaOx stimulation (Fig. [7a, b](#Fig7){ref-type="fig"}). The LC3B immunofluorescence assay confirmed that the level of autophagy was increased (Fig. [7c](#Fig7){ref-type="fig"}). Next, we hypothesized that FoxO3a transcriptionally activates LC3B expression. To verify this hypothesis, chromatin immunoprecipitation (ChIP) and qPCR assays were performed. We designed and synthesized ten pairs of primers of *lc3b* (Table [S1](#MOESM1){ref-type="media"}) for qPCR. After ChIP PCR, we selected two regions for further validation (Fig. [7d](#Fig7){ref-type="fig"}). Then, the LC3B promoter region in renal TEC DNA was inserted into the pGL3-enhancer luciferase reporter vector (Fig. [7e](#Fig7){ref-type="fig"}), and a luciferase assay was conducted. The luciferase activity was significantly increased when LC3B was co-transfected with FoxO3a. To identify the region in which FoxO3a interacts with LC3B, we constructed five pGL3LC3B expression plasmids with different mutation regions (Fig. [7f](#Fig7){ref-type="fig"}). The luciferase activity assay showed that all five mutated regions regulated the transcription of *lc3b* and that the first region played the most important role in the regulation of *lc3b* transcription (Fig. [7g](#Fig7){ref-type="fig"}).Fig. 7The Sirt3/FoxO3a pathway promoted autophagy by transcriptionally regulating LC3B in TEC.**a** The expression of the autophagy-associated proteins Beclin-1, Atg5 and Atg7 and the LC3 II/I ratio were detected by western blot. **b** The expression of Beclin-1, Atg5 and Atg7 and the LC3 II/I ratio were significantly upregulated by Sirt3 overexpression compared to the non-transfected control. **c** Immunofluorescence assays indicated LC3B upregulation with Sirt3 overexpression (DAPI: blue, LC3B: red). Scale bar: 60 μm. **d** Two pairs of *lc3b* primers were selected. **e** The LC3B promoter region in renal TEC DNA was inserted into the pGL3-enhancer luciferase reporter vector. **f** Five pGL3LC3B plasmids with different mutation regions were constructed. **g** The luciferase activity assay showed that all five mutated regions regulated the transcription of *lc3b* and that the first region played the most important role in the regulation of *lc3b* transcription. Data are shown as the means ± S.D.; *n* = 3 per group

Inducing autophagy ameliorated TEC injury {#Sec19}
-----------------------------------------

We further investigated whether increasing autophagy would ameliorate or exacerbate TEC injury. The autophagy inducer rapamycin and the autophagy inhibitor 3-MA were used. Flow cytometry analysis demonstrated that both apoptosis and necrosis of TEC were significantly decreased when autophagy was induced but were increased when autophagy was inhibited (Fig. [8a](#Fig8){ref-type="fig"}). TUNEL assays confirmed the differences in TEC apoptosis among these groups (Fig. [8b](#Fig8){ref-type="fig"}). In the rapamycin-treated group, the protein levels of cleaved caspase-3 and Bax were reduced, and the anti-apoptotic protein Bcl-2 was upregulated. In addition, the effects of rapamycin and 3-MA were verified by measurements of Beclin-1, Atg5 and Atg7 expression (Fig. [8c](#Fig8){ref-type="fig"}).Fig. 8Enhancement of autophagy ameliorated TEC injury under CaOx stimulation.**a** Flow cytometry was performed on TEC treated with the autophagy agonist rapamycin or the autophagy antagonist 3-MA. Both apoptosis and necrosis of TEC were significantly decreased when autophagy was induced but were increased when autophagy was inhibited. **b** TEC apoptosis was examined by the TUNEL assay. Induction of autophagy with rapamycin reduced apoptosis, and inhibition of autophagy increased apoptosis. Scale bar: 150 μm. **c** Autophagy- and apoptosis-associated proteins were detected by western blot. In the rapamycin-treated group, the cleaved caspase-3 and Bax levels were reduced, and the anti-apoptotic protein Bcl-2 was upregulated. Beclin-1, Atg5 and Atg7 expression levels were upregulated by rapamycin treatment and downregulated by 3-MA. Data are shown as the means ± S.D.; *n* = 3 per group

Discussion {#Sec20}
==========

Sirt3 is highly expressed in metabolically active tissues, such as kidney tissue^[@CR36]^, but only a few studies of Sirt3 in kidney diseases have been reported to date. In acute kidney injury (AKI), oxidative stress and mitochondrial damage are drivers of AKI-associated pathology^[@CR37]^. In a recent study, Morigi et al. found that promoting Sirt3 expression and activity with the AMPK agonist acadesine (AICAR) or the antioxidant agent acetyl-l-carnitine (ALCAR) improved renal function and decreased TEC injury in WT animals but had no effect on *Sirt3*^*−/−*^ mice^[@CR38]^. Moreover, *Sirt3*^*−/−*^ mice administered cisplatin and exhibited more severe AKI and more frequent death than WT animals, and neither AICAR nor ALCAR treatment prevented the death of Sirt3^*−/−*^ AKI mice^[@CR38]^. In renal clear cell carcinoma, increased Sirt3 expression was observed. Sirt3 depletion, as well as stable expression of the inactive mutant of Sirt3, inhibited cell proliferation and tumour growth^[@CR39]^. In the current study, reduced Sirt3 expression was observed in both in vivo and in vitro models. Restoring the Sirt3 levels via lentivirus transfection in vitro and resveratrol administration in vivo significantly decreased TEC death. In addition, CaOx-induced Sirt3 downregulation was reversed by MAPK signalling inhibition in TEC. MAPK pathway inhibitor treatment ameliorated nephrolithiasis in mice. Therefore, for the first time, our results demonstrate that downregulation of Sirt3 expression is a key factor in nephrolithiasis.

Apart from SB203580, PD98059 and SP6000125, other inhibitors seem to reduce necrotic and apoptotic cells as well. TEC injury could suffer from either oxidative stress or other signal pathways dysregulation at the same time, so those inhibitors may have a Sirt3-independent kidney protection. Based on the data we have, MAPK/Sirt3 is one important pathway to participate in the CaOx-induced TEC injury, apoptosis and necrosis. Although resveratrol is not a specific activator of Sirt3, which can also activate Sirt1^[@CR40]^, Sirt2^[@CR41]^ and Sirt5^[@CR42]^, resveratrol has been reported to be used as a Sirt3 agonist both in vitro and in vivo^[@CR28],[@CR29]^. Sirt3 protein level was rescued by resveratrol treatment, accompanied by lower TEC apoptosis and necrosis. This suggests that the kidney protection effect of resveratrol could potentially be dependent on the activation and function of Sirt3.

Sirt3 also regulates the activity of FoxO3a, and Sirt3 was implicated to form a physical interaction with FoxO3a in mitochondria via deacetylation^[@CR43]^. Non-acetylated FoxO3a has a higher affinity for DNA than the acetylated form, and mitochondrial Sirt3 could affect FoxO3a activity via deacetylation. FoxO3a can be activated by ROS, and gene silencing of FoxO3a enhanced ROS-induced apoptosis^[@CR44]^. Although Sirt3 is mainly localized to mitochondria, a recent study revealed that Sirt3 promoted nuclear translocation of the FoxO3a protein^[@CR45]^. Overexpression of Sirt3 enhanced the DNA-binding affinity of FoxO3a to the manganese superoxide dismutase (MnSOD) gene promoters and increased FoxO3a-dependent gene expression, and deacetylated FoxO3a was trapped inside the nucleus in microglia^[@CR45]^. Reducing the overwhelming oxidative stress is efficient in ameliorating renal TEC injury. In our study, CaOx induced upregulated FoxO3a acetylation levels and thus FoxO3a was unstable. Nevertheless, overexpression of Sirt3 resulted in reduced protein levels of phosphorylated FoxO3a at Ser253 and Ser318/321 in renal TEC. In vascular smooth muscle cells, phosphorylation of FoxO3a at Ser253 was reported in one study to repress FoxO3a activity and consequent MnSOD gene expression^[@CR46]^ and in another study to weaken the DNA-binding affinity of FoxO3a, facilitate FoxO3a nuclear export and prevent re-entry of FoxO3a into the nucleus by masking its nuclear localization sequence^[@CR47]^. The stability, subcellular localization, gene target specificity and transcriptional activity of FoxO3a are regulated by an intricate combination of post-translational modifications^[@CR48],[@CR49]^. Further, we found and validated that Sirt3 inhibits FoxO3a ubiquitination. Taken together, our findings show that CaOx downregulates Sirt3 expression and destabilizes FoxO3a by increasing its acetylation, phosphorylation and ubiquitination.

Tubular epithelial cells are dependent on autophagy to maintain homoeostasis, and there is complex crosstalk between autophagy and cell death^[@CR50]^. Enhanced autophagy protected proximal TEC^[@CR51]^ and prevented AKI^[@CR52]^. Recently, FoxO3a has been reported to induce autophagy^[@CR53]^. In haematopoietic stem cells, FoxO3a drives pro-autophagy gene programme, and ongoing autophagy allows cell survival^[@CR53]^. It is now well established that autophagy is a very sensitive process underlying cell responses induced by almost every stressful condition affecting cellular homoeostasis^[@CR54]^. Thus, it is possible that FoxO3a is an important upstream protein for regulating autophagy, and FoxO3a dysregulation may be an underlying mechanism that promotes TEC injury or even death under pathologic conditions. Similar to energy crisis, oxidative stress induced by CaOx stimulation places survival pressure on TEC. Oxidative stress through ROS production acts as the point of convergence of various stimuli and induces autophagy to sustain cell homoeostasis^[@CR55]^. However, in nephrolithiasis, the mechanism by which FoxO3a induces autophagy remains unclear. Interestingly, we have proved that FoxO3a can bind to the promoter region of LC3B, which is an important autophagy-related gene, and regulate its expression at the transcriptional level.

Autophagy and cell death often occur in the same cell, mostly in a sequence in which autophagy precedes cell death. This sequence of events is observed because stress often stimulates an autophagic response, especially if the level of stress is not lethal. Apoptotic and non-apoptotic cell death processes are activated when stress exceeds a critical duration or intensity^[@CR56]^. For instance, apoptosis and autophagy-associated cell death are two fundamental types of programmed cell death. An imbalance between apoptosis/necrosis and autophagy might facilitate CaOx-induced TEC injury. Here, we proved that CaOx induces TEC death via both apoptosis and necrosis. Induction of autophagy reduced TEC apoptosis and necrosis, while inhibition of autophagy promoted TEC apoptosis and necrosis. Therefore, restoring or even regulating the balance between apoptosis/necrosis and autophagy might be a therapeutic strategy for CaOx kidney stone formation.

The scheme presented in Fig. [9](#Fig9){ref-type="fig"} shows how Sirt3 protects TEC against cell death by modulating FoxO3a at the post-translational level and how active FoxO3a promotes autophagy. The figure also illustrates how CaOx inhibits Sirt3 expression via the MAPK pathway. Our data do not rule out other mechanisms, such as Sirt3-mediated activation of proteins or transcription factors aside from FoxO3a. However, the current study provides proof-of-principle evidence that the MAPK/Sirt3/FoxO3a pathway plays an important role in nephrolithiasis. Our data presented here show that Sirt3 is capable of ameliorating TEC injury by reducing apoptosis and necrosis and by inducing autophagy. These findings have profound implications for the management of not only nephrolithiasis but also many other kidney diseases that are associated with increased ROS production or TEC injury.Fig. 9Schematic diagram demonstrating the mechanism of CaOx-mediated TEC injury.In nephrolithiasis, CaOx activates the MAPK pathway members P38, ERK and JNK. Then, Sirt3 expression is inhibited. As a result, acetylation, ubiquitination and phosphorylation of FoxO3a are enhanced, leading to FoxO3a inactivation and dysfunction. Because functional FoxO3a binds to the promoter of *lc3b* and promotes autophagy, TEC autophagy is inhibited in nephrolithiasis

In conclusion, Sirt3 impairment through MAPK pathway activation leads TEC to apoptosis and necrosis via inhibition of FoxO3a acetylation, phosphorylation and ubiquitination. In contrast, activation of FoxO3a by wild- type Sirt3 overexpression or inhibition of the MAPK pathway restores and sustains autophagy to protect TEC from cell death by regulating LC3B transcription. Our study for the first time proves that the Sirt3FoxO3a interaction is protective against CaOx kidney stone formation and suggests that upregulating Sirt3 to moderate autophagy and cell death has potential for avoiding nephrolithiasis.
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